The cloud and the ocean have helped push Teledyne Technologies past the $2 billion mark. The Thousand Oaks-based industrial and defense conglomerate said Jan. 24 that its 2012 sales hit a record-busting $2.1 billion, up more than 9 percent from $1.9 billion a year before. Net income also set a record at $161.8 million, compared Read More →
After 47 years, the K-Swiss brand might be taking its first steps into the sunset. Westlake Village-based K-Swiss said Jan. 17 that it has agreed to a $170 million buyout by South Korean fashion and retail conglomerate E-Land World Limited. The sale comes after K-Swiss, the maker of the iconic white footwear that was the Read More →
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Shares of Westlake Village-based footwear firm K-Swiss soared 48 percent on the morning of Jan. 17 after the company agreed to a $170 million buyout. E.Land World Ltd. of South Korea offered to pay $4.75 per share for K-Swiss, which has struggled with huge losses in recent years as sales of its iconic white tennis Read More →
Santa Paula-based Limoneira Co. said fourth-quarter revenue jumped sharply but that it experienced a decline in profit because of expenses for Sheldon Ranch, a new 1,000-acre lemon and citrus leasehold that is expected to be profitable in 2013. The company said it expects strong results from those lemon and citrus in 2013, when it also Read More →
Ventura County’s technology corridor has kicked off 2013 with $173 million in deal activity. Thousand Oaks-based Nexsan Corp., a maker of hard-disk storage arrays for mid-sized businesses, said Jan. 2 that it had been acquired by Minnesota-based Imation Corp. for $120 million. Oxnard-based wireless products company CalAmp Corp. said Dec. 20 that it is buying Read More →
Thousand Oaks-based Amgen has entered a deal to pay up to $180.5 million for nanomedicine tumor treatments being developed by a Massachusetts company. Cambridge-based Bind Biosciences said it has entered a development agreement with Amgen for its kinase inhibitor nanomedicines for treating a range of solid tumors. The medicines are highly targeted and can be Read More →
